AI & Machine Learning Company in Minneapolis

Ranges, tied to scope, because the honest answer depends on how much of the work is data engineering rather than modeling. A feasibility engagement, meaning data profiling, label quality assessment, a baseline model, an offline evaluation, and a written go or no-go recommendation, typically runs USD 25,000 to 60,000 over four to eight weeks and it is the single best money most Twin Cities buyers spend. A production model deployment covering feature pipelines, training automation, a registered model, serving infrastructure, monitoring, and documentation typically runs USD 90,000 to 250,000 depending on how many upstream systems have to be integrated and how heavy the governance requirement is. A full machine learning platform build with a feature store, multi-model registry, drift and subgroup monitoring, CI for models, and a governance workflow your validation group signs off on runs USD 250,000 to 700,000 across phases. Regulated work costs more, and we say which parts and why: FDA-facing device software and bank model-risk validation both add substantial documentation and testing effort. Minneapolis engineering rates run well below San Francisco and New York while sitting above smaller Midwest markets, because Optum, Target, Medtronic, and U.S. Bank compete for the same candidates. Every engagement is priced fixed fee against a signed statement of work.

If the model is part of a device software function, the model is regulated, and the important shift in recent years is how the FDA handles model updates. Historically, retraining a model that changed its performance characteristics could require a new premarket submission, which meant device makers froze models at clearance and watched them degrade. The Predetermined Change Control Plan approach lets a manufacturer describe in the original submission what modifications it intends to make, the methods and data it will use, and the acceptance criteria and testing protocol, so that changes falling inside the authorized plan can be implemented without a new submission. That is an engineering requirement, not a regulatory affairs footnote. It means the training pipeline has to be reproducible, the data provenance has to be traceable, the evaluation protocol has to be executable on demand, and the performance boundaries have to be enforced in code. We build device-adjacent machine learning with versioned datasets, deterministic training runs, a locked evaluation suite, and documentation that maps directly onto the change control plan. We are not your regulatory consultant and we do not draft your submission, but we build so your regulatory team is assembling evidence rather than manufacturing it.

The MCDPA sits at Minn. Stat. 325M.10 through 325M.21, enacted as Laws 2024 chapter 121 and in force since July 31 2025. It applies to controllers doing business in Minnesota or targeting Minnesota residents that process personal data of at least 100,000 consumers annually, or 25,000 consumers where more than 25 percent of gross revenue comes from selling personal data, with a Small Business Administration based small business exemption. For a model, three provisions dominate. Opt-in consent is required for sensitive data, which includes health data, precise geolocation, and biometric data, so those features cannot silently enter a training set. Universal opt-out signals such as Global Privacy Control must be honored, and that obligation follows the data into your feature store, not just your website. And Minnesota gives consumers a right to question the result of profiling used in furtherance of decisions with legal or similarly significant effects, including the right to review the personal data used and have the decision reevaluated on corrected data. Deletion rights propagate too, which is why we build deletion into the feature pipeline and training corpus rather than only the source database. The practical modeling consequence is that your training data has a legal lineage as well as a technical one, and a model you cannot rebuild from a documented, consented corpus is a model you cannot defend.

Financial institutions here operate under long-established federal model risk management expectations, and the practical consequence is that a model without documentation, an owner, and independent validation cannot go to production regardless of how good its AUC is. We build to that from the start. Every model gets an inventory entry, a named business owner, a documented conceptual soundness argument explaining why this model form fits this problem, a data lineage record, an ongoing monitoring plan with defined thresholds, and a validation package your second-line group can test independently rather than take on trust. Where the model touches credit decisions we add fair-lending analysis with subgroup performance breakdowns and reason-code generation adequate for adverse action notices, because a model that cannot explain a denial creates a compliance problem the day it launches. Where the model touches insurance we account for Minnesota's insurance data security requirements at Minn. Stat. 60A.985 through 60A.9857, enacted in 2021 along NAIC model lines, which obligate licensees to run an information security program and to investigate and report cybersecurity events. We build the artifacts as we build the model, because retrofitting validation evidence onto a finished system is where budgets go to die.

For a lot of Minneapolis problems, the traditional model is the better answer and we will tell you so. Demand forecasting, credit scoring, propensity, yield prediction, defect detection, and predictive maintenance are almost always won by gradient boosted trees or a well-specified time series model, and reaching for a large language model there costs more, runs slower, explains itself worse, and performs no better. Generative models earn their place where the input or output is unstructured language, images, or documents: extracting structured fields from bills of lading and rate confirmations, drafting clinical or service documentation for human review, summarizing long case histories, generating code or test scaffolding, and semantic search across a document estate. A common winning pattern in the Twin Cities is a hybrid, where a generative model turns messy documents into structured features and a boosted-tree model makes the actual prediction, which keeps the decision explainable enough to survive Minnesota's profiling-rights requirements. We run a bake-off in the feasibility phase using your data and your metric, and we publish the losing results too. Picking the architecture on evidence takes about three weeks and saves months.

Twelve to twenty-six weeks for most production deployments, and the variance sits almost entirely in data readiness and governance load rather than modeling. Weeks 1 to 5 are feasibility: data profiling, label quality assessment, a baseline, an offline evaluation against your metric, MCDPA and where relevant Health Records Act scoping, and a written recommendation. Weeks 6 to 13 are build: feature pipelines, training automation, experiment tracking, model registry, the evaluation suite, and serving infrastructure. Weeks 14 to 19 are validation: shadow mode against live traffic, subgroup and fairness testing where the domain requires it, drift monitor calibration, security review, and sign-off from your governance function, which at a health system means the AI governance committee and at a bank means independent model validation. Weeks 20 to 26 are staged rollout, monitoring tuning, runbook handover, and retraining schedule agreement. Two things reliably extend this. FDA-facing device software adds documentation and testing that can double the validation phase. And a data estate spread across systems that disagree on definitions adds weeks up front, which is exactly why we refuse to skip the feasibility phase.